Skip to content

Study · Randomized controlled trial · n = 62 · 2003

2 results

GnRH agonist treatment before total laparoscopic hysterectomy for large uteri.

Seracchioli R, Venturoli S, Colombo FM, Bagnoli A, Vianello F, Govoni F, Guerrini M, Gualerzi B

The Journal of the American Association of Gynecologic Laparoscopists1 Aug 2003Cited by 30 (Europe PMC)

PMID14567804 (opens in a new tab)DOI10.1016/s1074-3804(05)60254-x (opens in a new tab)PepBankPUB-14567804
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with large uterine myomas, triptorelin reduced uterine volume while volume remained unchanged without treatment.

    In plain wordsIn women with large uterine myomas, triptorelin reduced uterine volume compared with no treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseUterine volume
    Study

    n = 62

    Comparator
    No treatment
    Outcome group
    Uterine fibroid outcomes · Reproductive and sexual health
    Studied dose
    11.25 mg depot · injection · 3 months before surgeryAs given in this study (human).

    Measurements

    Uterine volume reduction
    26.5%
    triptorelin

    Source sentences

    Summary
    Triptorelin decreased uterine volume, calculated by ultrasonography, by 26.5% in group A, whereas the volume remained unchanged in group B.
    2 context sentences
    Summary · context
    Sixty-two women with symptomatic uterine myomas (size 16-20 wks).
    Summary · context
    Before surgery, women were assigned, at a ratio of 1:1 by random selection, to receive injections of triptorelin depot 11.25 mg 3 months before surgery (group A) or no treatment (group B).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with large uterine myomas, uterine weight, operating time, and hemoglobin decline differed significantly between triptorelin and no treatment.

    In plain wordsIn women with large uterine myomas, uterine weight, operating time, and hemoglobin decline differed between triptorelin and no treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Direction not reportedUterine weight, operating time, and hemoglobin decline
    Study

    n = 62

    Comparator
    No treatment
    Outcome group
    Surgical outcomes · Reproductive and sexual health
    Studied dose
    11.25 mg depot · injection · 3 months before surgeryAs given in this study (human).

    Source sentences

    Summary
    Statistical differences were found between groups concerning uterine weight, operating time, and drop in hemoglobin level.
    2 context sentences
    Summary · context
    Sixty-two women with symptomatic uterine myomas (size 16-20 wks).
    Summary · context
    Before surgery, women were assigned, at a ratio of 1:1 by random selection, to receive injections of triptorelin depot 11.25 mg 3 months before surgery (group A) or no treatment (group B).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.